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A B S T R A C T
The peroxisome proliferator activated receptors (PPARs) are important drug targets in treatment of metabolic
and inflammatory disorders. Fibrates, acting as PPARα agonists, have been widely used lipid-lowering agents for
decades. However, the currently available PPARα targeting agents show low subtype-specificity and conse-
quently a search for more potent agonists have emerged. In this study, previously isolated oxohexadecenoic acids
from the marine algae Chaetoceros karianus were used to design a PPARα-specific analogue. Herein we report the
design, synthesis, molecular modelling studies and biological evaluations of the novel 3,5-disubstituted isoxazole
analogue 6-(5-heptyl-1,2-oxazol-3-yl)hexanoic acid (1), named ADAM. ADAM shows a clear receptor preference
and significant dose-dependent activation of PPARα (EC50=47 µM) through its ligand-binding domain (LBD).
Moreover, ADAM induces expression of important PPARα target genes, such as CPT1A, in the Huh7 cell line and
primary mouse hepatocytes. In addition, ADAM exhibits a moderate ability to regulate PPARγ target genes and
drive adipogenesis. Molecular modelling studies indicated that ADAM docks its carboxyl group into opposite
ends of the PPARα and -γ LBD. ADAM interacts with the receptor-activating polar network of amino acids
(Tyr501, His447 and Ser317) in PPARα, but not in PPARγ LBD. This may explain the lack of PPARγ agonism, and
argues for a PPARα-dependent adipogenic function. Such compounds are of interest towards developing new
lipid-lowering remedies.
1. Introduction
The peroxisome proliferator-activated receptors (PPARs) are ligand-
activated nuclear receptors (NRs) with crucial roles in regulation of
genes involved in a wide range of physiological processes. The PPARs
respond to endogenous ligands, such as metabolites of fatty acids, or
synthetic compounds.1–3 In response to ligand binding, the PPARs
heterodimerize with retinoid X receptor (RXR) and act on specific PPAR
response elements (PPREs) in chromatin. Ligand binding initiates con-
formational changes in the LBD that facilitates dissociation or recruit-
ment of transcriptional co-regulators, mainly carried out by the ligand-
dependent activation function 2 (AF2). In addition, posttranslational
modifications adjust the receptors’ affinity for co-regulators and
thereby determine whether a target gene is induced or repressed.3–5
The PPARs are well known for their control of genes involved in lipid
and glucose metabolism. Moreover, the PPARs are shown to encompass
important roles in mediating biological effects related to inflammation
and vascular function.6–8
The three PPAR subtypes identified in humans show a tissue specific
expression. The subtypes PPARα and PPARγ are highly expressed in
liver and adipose tissue, respectively, while PPARδ is more ubiquitously
expressed.9,10 Activation of PPARγ is essential for control of energy
conservation through regulation of genes involved in lipogenesis and
lipid storage.11,12 In parallel, PPARα is the subtype most known for its
effects in fatty acid disposal pathways. Through regulation of target
genes involved in fatty acid transport, activation and oxidation, PPARα
increases lipid uptake and energy expenditure in the liver.13,14
Given their key roles in multiple metabolic and inflammatory
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pathways, the PPARs are attractive targets for treatment of various
metabolic disorders, such as the metabolic syndrome and type 2 dia-
betes mellitus. These disorders are strongly associated with atherogenic
dyslipidaemia and increased risk of cardiovascular diseases (CVDs).15
Collectively, CVDs comprise the main cause of death among these pa-
tients,16 and thus therapeutic approaches toward these disorders aim to
reduce modifiable risk factors. A group of widely used lipid-lowering
drugs in this context is the fibrates, which act as PPARα agonists.17
Fibrates and other PPARα agonists effectively reduce levels of circu-
lating triglycerides and increase levels of anti-atherogenic HDL-C in
high-risk subjects.18–22 However, fibrates are low-affinity ligands for
PPARα, and currently available PPARα agonists generally show low
subtype selectivity. Furthermore, the efficacy of these agonists is lim-
ited due to dose-related adverse effects.23,24 Thus, efforts have been
made to develop new PPARα agonists that show higher levels of se-
lectivity and potency than the fibrates.24,25
We previously identified and isolated the two isomeric oxohex-
adecenoic acids (7E)-9-oxohexadec-7-enoic (OFAI, 2) and (10E)-9-ox-
ohexadec-10-enoic acid (OFAII, 3) from the marine microalga
Chaetoceros karianus (Fig. 1). These compounds exhibited PPARα/γ
dual agonist activity.26,27
We used these two natural occurring oxohexadecenoic acids for the
design of a potent and selective PPARα agonist (Fig. 1). Both OFAI and
OFAII contain a α,β-unsaturated ketone moiety exhibiting putative
cytotoxic effects as Michael acceptors. Such effects have been reported
by oxo-fatty acids towards PPARγ.28–30 One possible bioisosteric sub-
stitution for the Michael-acceptor is the 3,5-disubstituted isoxazole ring
(Fig. 1). In this paper we report the synthesis, extensive biological
evaluation and molecular modelling studies of this first generation
analogue 6-(5-heptyl-1,2-oxazol-3-yl)hexanoic acid, named ADAM (1).
2. Results and discussion
2.1. Chemistry
The synthesis of ADAM (1) began with the base catalysed con-
densation of 1-nonyne (4) with methyl nitroacetate (5) affording iso-
xazole 6 in 73% yield, see Scheme 1. The methyl ester in 6 was then
reduced to the corresponding aldehyde using diisobutylaluminium hy-
dride (DIBAL-H). The freshly synthesized aldehyde was subsequently
reacted in a Wittig olefination reaction with the ylide of commercially
available (4-carboxybutyl)triphenylphosphonium bromide (8), the
latter formed from the reaction with two equivalents of lithium bis
(trimethylsilyl)amide (LiHMDS). This provided the alkenoic acid 9 in
64% yield over the two steps. Quantitative hydrogenation over palla-
dium on carbon of 9 finalized the synthesis of ADAM (1). The spec-
troscopic data were in agreement with the chemical structure (Sup-
porting information).
2.2. Docking studies
Docking of ADAM (1), OFAI (2) and OFAII (3) into the PPARα
LBD gave VLS (virtual ligand screening) scoring values in the range
of −35.1 to −29.4 for all compounds, and showed that the car-
boxylic group of all three compounds interacts with a hydrogen
bonding network of polar amino acids that includes Ser280, Tyr314,
His440, and Tyr464 (Fig. 2A, B). In the highest scored docking pose,
the oxygen atom of the carbonyl group of ADAM forms hydrogen
bonds with Ser280 (2.1 Å), Tyr314 (2.2 Å), Tyr464 (3.2 Å) and
His440 (3.4 Å), while the hydroxyl group is located within a network
of Tyr464 (3.7 Å), His440 (3.3 Å), Tyr464 (3.6 Å) and Tyr414 (3.5 Å)
(Fig. 2B). The carbonyl oxygen of OFAI forms hydrogen bonds with
Ser280 (2.2 Å), Tyr314 (2.1 Å), His 440 (3.4 Å) and Tyr464 (3.2 Å),
while the hydroxyl group is located closest to Tyr464 (3.6 Å) and
His440 (3.4 Å). The oxygen carbonyl of OFAII is involved in a hy-
drogen bonding network with Ser280 (2.1 Å), Tyr314 (2.2 Å), Tyr464
(3.2 Å) and His440 (3.4 Å), while the hydroxyl group is closest to
Tyr464 (3.1 Å) (Fig. 2A).
Docking of the compounds into PPARγ showed poses quite similar
to the PPARα poses (Fig. 2C, D). In addition, binding poses with the
carboxylic group in the direction of Arg316 and Glu323 were observed
for all compounds. For ADAM, this pose obtained the most favorable
scoring value (‐26.0 in the 2VST structure), with the carbonyl oxygen
1.6 Å from the side chain of Arg316 and the hydroxyl hydrogen 2.0 Å
from the side chain of Glu323 (Fig. 2D). For OFAI/II poses similar to the
orientation in PPARα were dominating with interactions between the
carboxylic group oriented into the polar network of Ser317, His351,
His477, Tyr355 and Tyr501 (Fig. 2C). The corresponding scoring value
was −26.1 for OFAI (in the 2VVO structure) and −27.7 for OFAII (in
the 2VV4 structure). The carbonyl oxygen of OFAI forms a hydrogen
bond with His477 (1.6 Å), while the hydroxyl oxygen participates in a
hydrogen bond with the side chain of Ser317 (1.8 Å), and the hydroxyl
hydrogen forms a hydrogen bond with the side chain of His351 (2.3 Å)
and Tyr501 (3.4 Å). The carbonyl oxygen of OFAII forms a hydrogen
bond with Ser317 (1.6 Å), while the hydroxyl group donates a hydrogen
bond to Tyr501 (2.1 Å), His477 (2.9 Å) and is acceptor for a hydrogen
bond from His477 (1.7 Å). It seems like the binding of OFAI to PPARγ is
Fig. 1. Chemical structures of OFAI (2) and OFAII (3) and the synthetic iso-
xazole ADAM (1).
Scheme 1. Synthesis of ADAM. (a) DABCO, EtOH, 80 °C, 73 h; (b) DIBAL-H, dry
CH2Cl2, −78 °C, 6 h; (c) LiHMDS, BrPh3P(CH2)4CO2H (8), THF, −78 °C to rt,
18 h; (d) H2, Pd/C, EtOAc, 12 h.
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stabilized by shorter hydrogen bonds to the polar network than the
binding to PPARα.
2.3. Biological assays
2.3.1. Dose-response and cytotoxicity
In order to assess the agonist activity and specificity of ADAM (1),
we performed dual-luciferase assays with GAL4 tethering constructs
where the LBD of different nuclear receptors were fused in frame with
GAL4 DNA-binding domain (DBD), enabling us to compare the ADAM
agonist activity from different NRs on the same GAL4-responsive luci-
ferase reporter. Cytotoxicity was determined simultaneously by mea-
surement of lactate dehydrogenase (LDH) in cell media. In addition,
cytotoxicity was assessed in standard XTT-based assays.
These experiments revealed that ADAM displayed a sigmodial dose-
response with respect to PPARα agonist activity, and an EC50 value of
47 µM (Fig. 3A). Given that the parent compounds are dual PPARα/γ
agonists and that ADAM showed a relatively high docking score for
PPARγ, we also assessed whether ADAM could activate PPARγ. As can
be seen from Fig. 3B, a minor induction of PPARγ activity was observed
at concentrations in the millimolar range, with an estimated EC50 value
of 2.0mM. This indicated a lack of PPARγ agonism.
Cell viability decreased at concentrations of 10-4 M ADAM in both
LDH and XTT assays (Fig. 3C, D), with rapid reduction to respectively
60 % and 40 % at 10-3 M.
Since ADAM had low to no activity towards PPARγ, while docking
indicated PPARγ binding, we also assayed its ability to act as a neutral
or inverse agonist 31 by allowing it to compete with the classical PPARγ
agonist Rosiglitazone. As can be seen from Fig. 4, even the highest
millimolar concentrations of ADAM was unable to outcompete 1.0 µM
Rosiglitazone.
2.3.2. Selective PPARα agonist activity
To assess the selectivity of ADAM with respect to nuclear receptor
agonist activity, we transfected COS-1 cells with GAL4-LBD fusion
constructs of different nuclear receptors LBDs, and treated them with
increasing concentrations of ADAM. The ADAM concentrations applied
were based on the empirical EC50 values determined previously (Fig. 3).
As expected, human PPARα activity was significantly induced upon
treatment with both 25 and 50 µM ADAM (Fig. 5). A minor PPARδ and
–γ agonist activity were observed, but the induction was not significant
in the model used. ADAM activated none of the other NR-LBD fusion
proteins under these conditions. The in vitro cell-based reporter assays
revealed that ADAM behaved as a specific PPARα agonist. When
compared to the known PPARα agonist Pirinixic acid, ADAM demon-
strated an about 2.5-fold greater efficacy in activating PPARα (Fig. 6).
We proceeded to evaluate the ability of ADAM to activate natural
PPARα- and PPARγ-regulated promoters, in order to study the agonist
activity in a more relevant context. ADAM was able to significantly
activate the PPARα target gene promoter CPT1A (Fig 7A), but not the
PPARγ target gene promoter PLIN1 (Fig. 7B). The CPT1A activation was
dependent on both full-length PPARα and a functional PPRE.
2.3.3. Activation of endogenous PPARα target genes in hepatocytes
To investigate the effects of ADAM on endogenous, chromatinized
PPAR target genes, we used two separate hepatocyte models; the
human hepatocellular carcinoma cell line Huh7 and primary mouse
hepatocytes. Of all the genes analysed, the induction of CPT1A/Cpt1a
expression was the most prominent. As can be seen from Fig. 8, this
gene was significantly upregulated by ADAM, comparable to the PPARα
agonists Pirinixic acid and GW7647, both in Huh7 cells and primary
mouse hepatocytes. The relative expressions of PPARA, SCD and
SREBF1 were unaffected by any of the treatment in Huh7 cells.
Fig. 2. ADAM, OFAI and OFAII docked into the LBD X-ray crystal structures of PPARα and PPARγ. Binding mode of the oxohexadecenoic acids OFAI and OFAII, and
the analogue ADAM after docking into the ligand-binding domain of human PPARα (A, B; PDB entry 2P54) and PPARγ (C, D; PDB entry 2VV0). The figure shows the
superposition of receptor–ligand complexes where the X-ray structures of the PPARs are shown as ribbon representation (PPARα in grey and PPARα in blue). Ball and
stick models are used for the ligands (carbon-yellow, nitrogen-blue, oxygen-red, hydrogen-white) and central side groups (carbon and hydrogen-pink, nitrogen-blue,
oxygen-red).
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However, in primary mouse hepatocytes Scd1 and Srebf1 were sig-
nificantly induced by ADAM, which grouped together with the other
PPARα agonists GW7647 and Pirinixic acid. The parental oxohex-
adecenoic acids OFAI (2) and OFAII (3) seemed to group with Ro-
siglitazone and induced the expression of Ppara while having no effect
on the Scd1 and Srebf1 expression in primary mouse hepatocytes. This is
in line with what we have observed earlier for the OFAs in Huh7.27
2.3.4. Adipocyte differentiation
We continued to study the activation of adipocyte-specific PPAR
target genes, using the human Simpson-Golabi-Behmel syndrome
(SGBS) pre-adipocyte cell line.32 By exchanging the PPARγ-agonist
Rosiglitazone, which is an essential component in the differentiation
medium, with ADAM, Pirinixic acid, OFAI, OFAII or DMSO, we could
evaluate the compound’s effects on target gene activation and cell
morphology changes. As expected, Rosiglitazone induced the expres-
sion of most PPARγ target genes during the course of differentiation
(Fig. 9). Surprisingly, ADAM also induced expression of genes involved
in adipogenic differentiation (PPARG, CEBPA), lipid metabolism and
storage (ACSL1, CD36, FABP4, PLIN1) and adipokine expression
(ADIPOQ, ANGPTL4). On a general basis, the effect of ADAM on relative
expression levels of PPARγ target genes appears similar to that of Pir-
inixic acid, lower than Rosiglitazone, and higher than OFAI and -II.
To evaluate the effects of ADAM on adipocyte differentiation at the
morphological level, we stained the treated SGBS cells with Oil Red O.
Rosiglitazone was, as anticipated, the most potent promoter of lipid
droplet formation, i.e. adipocyte differentiation, although Pirinixic acid
also exhibited a clear adipogenic potential (Fig. 10). Mirroring what
was observed at the gene expression level, ADAM seems to promote
adipocyte differentiation to a higher extent than OFAI and –II, but to a
considerably lesser extent than both Rosiglitazone and Pirinixic acid
(Fig. 10).
Fig. 3. ADAM activates PPARα and displays low
cytotoxicity at EC50. The assays were run with
GAL4-DBD-NR-LBD chimeric constructs in COS-
1 cells, using LBD from human PPARα and PPARγ,
respectively. The graphs show the dose–response
relationship for ADAM with respect to human
PPARα (A) and PPARγ (B), normalized to the ac-
tivity measured with empty vector (GAL4 only).
Corresponding cytotoxicity data were obtained by
measuring lactate dehydrogenase (LDH) in media or
(C) by running XTT based assays (D). The data re-
present three biological replicates analysed in
quadruplicates, and are presented as mean ± SEM.
RLU, Relative light units. The stapled red lines in-
dicate the EC50-value for PPARα activation.
Fig. 4. ADAM is unable to outcompete Rosiglitazone in activation of PPARγ.
The assays were run with GAL4-DBD-PPARγ-LBD chimeric construct in COS-
1 cells. The graph shows the inverse PPARγ agonism dose–response for ADAM
when titrated against 1.0 µM Rosiglitazone, normalized to the activity mea-
sured with empty vector (GAL4 only). The data represent three biological re-
plicates analysed in quadruplicates, and are presented as mean ± SEM. RLU,
Relative light units.
Fig. 5. ADAM shows agonist activity specific for PPARα. The assays were run
with GAL4-DBD-NR-LBD chimeric constructs in COS-1 cells, using the ligand
binding domain (LBD) from human nuclear receptors. The cells were treated
with 0, 25 or 50 µM of ADAM dissolved in DMSO (final concentration 0.1 %), as
indicated in the legend. The data represent three biological replicates analysed
in quadruplicates, normalized to respective DMSO control (0 µM) and GAL4,
and are presented as mean ± SEM. Statistical differences were analyzed using
two-way ANOVA followed by Bonferroni’s correction for multiple comparisons.
Adjusted p-value ***p≤ 0.001 compared to DMSO (0 µM ADAM) control. RLU,
Relative light units.
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Although PPARγ is the PPAR subtype predominantly expressed in
white adipocytes, the effects observed upon ADAM and Pirinixic acid
treatment in this study indicates a function for PPARα in these cells.
The role of PPARα in white adipose tissue (WAT) is still not fully un-
derstood, but previous studies have pointed towards an involvement in
WAT metabolism and differentiation.33–35 Induction of ADIPOQ ex-
pression in mouse WAT and human subjects with PPARα agonists have
previously been reported.36 Goto et al. 37 have shown that PPARα ac-
tivation induced adipocyte differentiation with limited lipid
accumulation in 3T3-L1 adipocytes as well as in mice WAT. They fur-
ther hypothesized that PPARα are involved in driving adipocyte hy-
perplasia but not hypertrophy.
The strong and continuous increase in PPARγ target expression
observed upon Rosiglitazone treatment may be attributed to this ago-
nist’s ability to induce production of endogenous ligands. Increased
levels of the CD36 scavenger receptor, which mediates uptake of lipid
particles including oxidized LDL (oxLDL), could provide the cell with
hydroxyoctadecadienoic acids (HODEs) and hydroxyeicosatetraenoic
acids (HETEs) which are known PPARγ agonists and components of
oxLDL.38–40 Alternatively, induction of the rate-limiting enzyme in
prostaglandin synthesis, COX2, could provide the cells with other nat-
ural ligands, like 15d-PGJ2.41,42 While ADAM might be able to drive
some of these processes, another possibility is that metabolites pro-
duced in PPARα-mediated processes may activate PPARγ. Fatty acids
induce their own breakdown through activation of PPARα.43,44 As ac-
tivated PPARα leads to upregulation of CYP4A which mediates ω-hy-
droxylation, metabolites produced during catabolism of PPARα ligands
may in turn activate PPARγ.45
To discriminate between these alternative adipogenic functions of
ADAM, more sophisticated experiments will have to be conducted,
combining conditional knock-down of PPARα and PPARγ with agonist
treatment in SGBS cells or preferably primary adipocytes from healthy
donors. This is however beyond the scope of the current paper.
The X-ray crystal structures of receptor-agonist complexes show that
the acidic head groups of the agonists form a hydrogen bonding net-
work with a polar part of the LBD that includes amino acids such as
Ser317, His351, Tyr355, His477 and Tyr501 in PPARγ.46 These inter-
actions are crucial for stabilizing the AF2 domain in a conformation for
coactivator binding and receptor activation. The PPARα docking in-
dicates that ADAM, OFAI and OFAII form a hydrogen bonding network
with the corresponding network of polar amino acids (Fig. 2A and B).
However, in PPARγ the docking also indicated an alternative binding
pose with the polar head group interacting strongly with Arg316 and
Glu323 (Fig. 2C and D). These amino acids form a strong polar region
close to the part of the LBD where the agonist’s aliphatic tail usually
interacts. PPARα has a threonine (Thr279) at a position corresponding
to Arg316 PPARγ, indicating that this area is less polar in PPARα than
in PPARγ. For ADAM, the alternative pose was the best scored, in-
dicating that the polar head group interacts with Arg316 and Glu323.
This suggests that ADAM is not able to interact with the receptor-acti-
vating polar network of amino acids, and hence not able to stabilize the
AF2 domain of PPARγ in a conformation for coactivator recruitment
and receptor activation.47 Taken together, this seems to be the most
plausible explanation for the lack of PPARγ agonism and argues for a
PPARα-dependent adipogenic function of the oxohexadecenoic acid
analogue ADAM.
Fig. 6. ADAM demonstrates a greater efficacy in activating PPARα than
Pirinixic acid. The assays were run with GAL4-DBD-PPARα-LBD chimeric
constructs in COS-1 cells. The cells were treated with 0, 25 or 50 µM of ADAM
or Pirinixic acid (PIRI) dissolved in DMSO (final concentration 0.1 %), as in-
dicated in the legend. The Luciferase activity data, representing three biological
replicates analysed in quadruplicates, were normalized to GAL4 empty vector
and DMSO control, and presented as mean ± SEM. Statistical differences were
analyzed using two-way ANOVA followed by Bonferroni’s correction for mul-
tiple comparisons. Significant differences in PPARα activation are denoted by
asterisks (*) for ADAM versus Pirinixic acid treatment, and hash (#) for treated
(25/50 μM) versus respective untreated groups (0 μM). Adjusted p-values
**p≤ 0.01, ***p≤ 0.001, #p≤ 0.05, ##p≤ 0.01, ###p≤ 0.001. RLU, Relative
light units.
Fig. 7. ADAM activates human promoters in a
PPARα/PPRE dependent fashion. COS-1 cells were
transfected with plasmids expressing (A) full-length
human PPARα, RXRα, and a CPT1A-driven reporter
as wild-type (WT; black bars) or with mutated PPRE
(white bars), or (B) full-length human PPARγ,
RXRα, and a PLIN1-driven reporter as wild-type
(black bars) or with mutated PPRE (white bars). The
cells were treated with 50 µM ADAM dissolved in
DMSO (final concentration 0.1 %). The Luciferase
activity data, representing three biological replicates
analysed in quadruplicates, were normalized to the
DMSO control, and presented as mean ± SEM.
Statistical differences were analyzed using two-way
ANOVA followed by Bonferroni’s correction for
multiple comparisons. Differences between groups
on the wild-type promoters are indicated by aster-
isks; adjusted p-values **p≤ 0.01. RLU, Relative
light units.
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3. Conclusions
Molecular modelling studies and pharmacological characterization
of the novel synthetic 3,5-disubstituted isoxazole analogue 6-(5-heptyl-
1,2-oxazol-3-yl)hexanoic acid ADAM (1) showed specific activation of
PPARα. The molecular modelling experiments suggest that ADAM is
unable to interact with the receptor-activating polar network of amino
acids in PPARγ, necessary for AF2 stabilization and coactivator re-
cruitment. However, ADAM regulates important PPAR target genes in
both hepatocytes and adipocytes. Whether the apparent induction of
adipocyte differentiation seen with ADAM in the SGBS model is due to
PPARγ or PPARα-dependent target gene activation needs to be studied
further. However, the molecular modelling analysis and data from
specificity assays point in the direction of the latter.
4. Material and methods
4.1. General
Unless stated otherwise, all commercially available reagents and
solvents were used in the form they were supplied without any further
purification. The stated yields are based on isolated material. Melting
points were measured using a Barnstead Electrothermal IA9200 melting
point apparatus. Thin layer chromatography was performed on silica
gel 60 F254 aluminum-backed plates fabricated by Merck. Flash column
chromatography was performed on silica gel 60 (40–63 µm) produced
by Merck. NMR spectra were recorded on a Bruker AVII400 or a Bruker
DPX300 spectrometer at 400MHz or 300MHz respectively for 1H NMR
and at 100MHz or 75MHz respectively for 13C NMR. Coupling con-
stants (J) are reported in hertz and chemical shifts are reported in parts
per million (δ) relative to the central residual protium solvent re-
sonance in 1H NMR (CDCl3= δ 7.27) and the central carbon solvent
resonance in 13C NMR (CDCl3= δ 77.00). Mass spectra and high re-
solution mass spectra were recorded at 70 eV on Micromass Prospec Q
or Micromass QTOF 2W spectrometer using ESI as the method of io-
nization.
4.2. Synthesis of compounds
4.2.1. Methyl 5-heptylisoxazole-3-carboxylate (6)
Methyl nitroacetate (5) (500mg, 4.47mmol) and 1-nonyne (4)
(434mg, 3.50mmol) were dissolved in absolute EtOH (6.8 mL). DABCO
(26.4 mg, 0.24mmol) was added and the mixture was heated to 80 °C.
After 72 h at 80 °C, the mixture was concentrated under vacuum. The
crude product was purified by silica gel column chromatography
(hexane-EtOAc 9:1). White solid (575mg, 73%). m.p: 48–49 °C. 1H
NMR (400MHz, Chloroform-d) δ 6.41 (s, 1H), 3.96 (s, 3H), 2.80 (t,
J=7.6 Hz, 2H), 1.71 (p, J=7.5 Hz, 2H), 1.57–1.20 (m, 8H), 0.88 (t,
J=6.9 Hz, 3H). 13C NMR (101MHz, CDCl3) δ 175.9, 160.7, 156.0,
101.4, 52.8, 31.6, 28.9, 28.8, 27.4, 26.7, 22.6, 14.0. Rf= 0.46; (EtOAc-
hexane 3:7), HRMS (ESI): calculated C12H19NO3Na: 248.1257, found:
248.1257.
4.2.2. 5-Heptylisoxazole-3-carbaldehyde (7)
A solution of ester 6 (300mg, 1.33mmol, 1.00 equiv.) in anhydrous
CH2Cl2 (6.0mL) was cooled to −78 °C under argon atmosphere and
slowly treated over 5 minutes with a solution of diisobutylaluminum
hydride (DIBAL-H) (1.62mL, 1.0M in CH2Cl2, 1.62mmol, 1.20 equiv.).
The reaction mixture was stirred at −78 °C for 6 h and then quenched
with ice. A sat. aq. solution of Rochelle-salt (10mL) was added. The
phases were separated and the aq. phase was extracted with CH2Cl2
(3×10mL). The combined organic layers were dried (MgSO4), before
it was concentrated in vacuo. The resultant residue was purified by silica
gel column chromatography (hexane-EtOAc 9:1). Clear oil (220mg,
81%). 1H NMR (300MHz, Chloroform-d) δ 10.12 (s, 1H), 6.37 (s, 1H),
2.81 (t, J=7.6 Hz, 2H), 1.72 (p, J=7.4 Hz, 2H), 1.43–1.21 (m, 8H),
0.88 (t, J=6.4 Hz, 3H). 13C NMR (101MHz, CDCl3) δ 185.3, 176.3,
162.3, 98.1, 31.8, 29.1, 29.0, 27.5, 26.8, 22.7, 14.2. Rf= 0.53;
(hexane-EtOAc 8:2), HRMS (ESI): calculated C11H17NO3Na: 218.1151,
found: 218.1151.
4.2.3. (Z)-6-(5-heptylisoxazol-3-yl)hex-5-enoic acid (9)
To (4-carboxybutyl)triphenylphosphonium bromide (8) (545mg,
1.23mmol, 2.0 equiv.) in THF (20mL) was added LiHMDS (2.46mL,
Fig. 8. ADAM activates endogenous PPARα target genes in (A) human hepatocarcinoma cells and (B) primary mouse hepatocytes. The cells were treated with 50 µM
ADAM, 50 µM PIRI, 1 µM ROSI, 1 µM GW7647, 50 µM OFAI, or 50 µM OFAII for 18 hours before harvested for qPCR analysis. The data represent two biological
replicates analysed in duplicates, normalized to the respective DMSO controls, and are presented as mean ± SEM. Statistical differences were analyzed using one-
way ANOVA followed by Bonferroni’s correction for multiple comparisons. Adjusted p-values *p≤0.05, **p≤ 0.01, and ***p≤ 0.001 compared to DMSO control.
PIRI, Pirinixic acid; OFAI, (7E)-9-oxohexadec-7-enoic acid; OFAII, (10E)-9-oxohexadec-10-enoic acid; ROSI, Rosiglitazone.
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1.0M in THF, 4.0 equiv.) slowly at −78 °C. The solution was heated to
room temperature and stirred for 30min before being cooled to −78 °C
again. Aldehyde 7 (120mg, 0.61mmol, 1.0 equiv.) in THF (5mL) was
added at −78 °C. The solution was allowed to slowly warm up to room
temperature in a dry ice/acetone bath for 16 h before it was quenched
with aq. NH4Cl (15mL). Et2O (15mL) was added and the phases were
separated. The aqueous phase was extracted with Et2O (2×15mL) and
the combined organic layers were washed with brine (20mL), dried
(Na2SO4) and then concentrated in vacuo. The resultant residue was
purified by silica gel column chromatography (hexane-EtOAc 1:1).
Fig. 9. ADAM activates endogenous PPARγ target genes in human adipocytes. Differentiation of SGBS cells was initiated with differentiation medium supplied with
either 0.1 % DMSO (white bars), 25 µM ADAM, 25 µM OFAI, 25 µM OFAII, 25 µM PIRI, or 2 µM ROSI (black bars) on day 0, and gene expression measured by qPCR on
day 0, 4, 8, and 12. The data represent minimum three biological replicates analysed in duplicates, normalized to day 0 (D0), and are presented as mean ± SEM.
Statistical differences were analyzed using two-way ANOVA followed by Bonferroni’s correction for multiple comparisons. Adjusted p-values *p≤0.05, **p≤ 0.01,
and ***p≤0.001 compared to DMSO control for each time point. PIRI, Pirinixic acid; OFAI, (7E)-9-oxohexadec-7-enoic acid; OFAII, (10E)-9-oxohexadec-10-enoic
acid; ROSI, Rosiglitazone.
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Clear oil at room temperature (solidifies in freezer) (136mg, 79%). 1H
NMR (300MHz, Chloroform-d) δ 9.50 (bs, 1H), 6.29 (dt, J=11.6,
1.7 Hz, 1H), 5.99 (s, 1H), 5.91 (dt, J=11.6, 7.4 Hz, 1H), 2.72 (t,
J=7.6 Hz, 2H), 2.51 (qd, J=7.5, 1.7 Hz, 2H), 2.42 (t, J=7.5 Hz, 2H),
1.82 (p, J=7.5 Hz, 2H), 1.69 (p, J=7.5 Hz, 2H), 1.41–1.19 (m, 8H),
0.92–0.83 (m, 3H). 13C NMR (101MHz, CDCl3) δ 179.3, 173.5, 159.9,
137.6, 117.9, 101.3, 33.5, 31.8, 29.2, 29.0, 28.9, 27.7, 26.8, 24.3, 22.8,
14.2. Rf= 0.18; (CH2Cl2/MeOH 95:5), HRMS (ESI): calculated
C16H25NO3Na: 302.1727, found: 302.1727.
4.2.4. 6-(5-Heptyl-1,2-oxazol-3-yl)hexanoic acid (ADAM, 1)
10% Pd/C (5mg) was added to a solution of the alkenoic acid 9
(40mg, 0.14mmol) in EtOAc (5mL). The reaction flask was evacuated
and flushed with H2. This procedure was repeated three times. The
mixture was stirred at room temperature for 12 h under H2 and filtered
through a pad of Celite. The filtrate was concentrated to give the sa-
turated product. Pale beige solid (38mg, 94%). m.p: 37–38 °C. 1H NMR
(400MHz, Chloroform-d) δ 10.12 (bs, 1H), 5.80 (s, 1H), 2.68 (t,
J=7.7 Hz, 2H), 2.62 (t, J=7.6 Hz, 2H), 2.35 (t, J=7.5 Hz, 2H),
1.72–1.58 (m, 6H), 1.46–1.19 (m, 10H), 0.97–0.80 (m, 3H). 13C NMR
(101MHz, CDCl3) δ 179.6, 173.6, 163.8, 100.4, 34.0, 31.8, 29.2, 29.0,
28.7, 28.0, 27.6, 26.9, 26.0, 24.5, 22.7, 14.2. Rf= 0.18; (CH2Cl2/MeOH




The pSG5-GAL4, pSG5-GAL4-hPPARα-LBD, pSG5-GAL4-hPPARδ-
LBD and pSG5-GAL4-hPPARγ-LBD, pSG5-GAL4-hLXRα-LBD, pSG5-
GAL4-hLXRβ-LBD, and pSG5-GAL4-hRXRα-LBD plasmids encoding a
GAL4 DNA-binding domain (DBD; aa 1-147) fused in frame with SV40
Nuclear localization signal 1 (NLS1), and LBD of human PPARα,
PPARδ, PPARγ, LXRα, LXRβ, and RXRα have been described before.27
The plasmids encoding FLAG-tagged full-length human PPARα, PPARγ,
and RXRα have been described earlier.26,48 The pGL3-5×UAS-SV40
luciferase reporter, as well as the human PLIN1-driven reporters, pGL3-
hPLIN1-3′del and pGL3-hPLIN1-3′del PPREmut, have also been pre-
viously described.11,26 The human CPT1A-driven reporters, pGL3-
hCPT1AInt and pGL3-hCPT1AInt PPREmut, were received as a gift from
Prof. Diego Haro Bautista and have been described previously.49 The
vector pRL-CMV (Promega, Madison, WI), constitutively expressing
Renilla Luciferase, was used as a control of transfection efficiency. All
cloned plasmids have been sequenced, and cloning primer sequences
are available upon request.
4.3.2. Cell culture
COS-1 cells were maintained in high glucose Dulbecco’s modified
Eagle’s medium (DMEM; Sigma-Aldrich, #D6546) enriched with 10 %
heat-inactivated fetal bovine serum (FBS; Sigma-Aldrich, #F7524),
4 mM L-Gln (Sigma-Aldrich, #G7513) and 50 U/mL penicillin/50 µg/
mL streptomycin (Sigma-Aldrich, #P4458) at 37 °C in a humidified
atmosphere of 5 % CO₂ in air. Cell confluence never exceeded 80 %
prior to sub-culturing or transfection.
HuH-7 cells were maintained in high glucose DMEM (Sigma-
Aldrich, #D6546) enriched with 10 % heat-inactivated FBS (Sigma-
Aldrich, #F7524), 4 mM L-Gln (Sigma-Aldrich, #G7513), 50 U/mL
penicillin/50 µg/mL streptomycin (Sigma-Aldrich, #P4458) and ITS
(10 ng/mL insulin, 5.5 ng/mL transferrin, 5 pg/mL selenium; Sigma-
Aldrich, #I3146) at 37 °C in a humidified atmosphere of 5 % CO₂ in air.
Human Simpson-Golabi-Behmel Syndrome (SGBS) cells were cul-
tured in DMEM/Nutrient Mix F12 Ham (Sigma-Aldrich, #D6421) with
10 % non-inactivated FBS (Sigma-Aldrich, #F7524), 4 mM L-Gln
(Sigma-Aldrich, #G7513), and 50 U/mL penicillin/50 µg/mL strepto-
mycin (Sigma-Aldrich, #P4458), supplemented with a vitamin mix of
8mg/mL biotin (Sigma-Aldrich, #B4639) and 4mg/L D-pantotenate
(Sigma-Aldrich, #P5155), for 4 days prior to differentiation. The SGBS
cells were differentiated into adipocytes as previously described.32 To
initiate differentiation, medium was changed to a culture medium
without FBS, supplemented with human 0.01mg/mL apo-transferrin
(Sigma-Aldrich, #T4382), 20 nM human insulin (Sigma-Aldrich,
#I2643), 0.2 nM triiodythyronine (Sigma-Aldrich, #T6397), 100 nM
hydrocortisol (Sigma-Aldrich, #D2915), 500 μM IBMX (Sigma-Aldrich,
#I5879) and 25 nM dexamethasone (Sigma-Aldrich, #D2915), with
addition of 25 µM ADAM, 25 µM Pirinixic acid (PIRI; WY-14643;
C7081, Sigma-Aldrich) 25 µM (7E)-9-oxohexadec-7-enoic (OFAI),
25 µM (10E)-9-oxohexadec-10-enoic acid (OFAII), 2 µM Rosiglitazone
(ROSI; BRL-49653, Cayman chemical, Ann Arbor, MI), or 0.1 % DMSO.
After 4 days, medium was changed to a culture medium without FBS,
supplemented with human 0.01mg/mL apo-transferrin (Sigma-Aldrich,
#T4382), 20 nM human insulin (Sigma-Aldrich, #I2643), 0.2 nM
triiodythyronine (Sigma-Aldrich, #T6397), 100 nM hydrocortisol
(Sigma-Aldrich, #D2915), that was renewed at day 8. The culture was
terminated at day 12. Cells were harvested for RNA isolation and
stained with Oil Red O at day 0, 4, 8, and 12.
4.3.3. Primary hepatocytes
All animal use was approved and registered by the Norwegian
Animal Research Authority. Mice were housed in a temperature
Fig. 10. ADAM drives accumulation of lipids in human adipocytes.
Differentiation of SGBS cells was initiated with differentiation medium supplied
with either 0.1 % DMSO, 25 µM ADAM, 25 µM OFAI, 25 µM OFAII, 25 µM PIRI,
or 2 µM ROSI. The pictures show representative areas of wells with cells stained
with Oil Red O at day 0, 4, 8, and 12 after onset of differentiation. PIRI,
Pirinixic acid; OFAI, (7E)-9-oxohexadec-7-enoic acid; OFAII, (10E)-9-oxohex-
adec-10-enoic acid; ROSI, Rosiglitazone.
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controlled (22 °C) facility with a strict 12 h light/dark cycle. Male
C57BL/6N mice (Jackson Laboratory) aged 7–8 weeks were used to
isolate primary hepatocytes. Mice were first anaesthetised with iso-
flurane (AbbVie) and then their livers were perfused via the portal vein
with liver perfusion medium (Thermo Fisher Scientific, #17701038) for
15min (2mL/min) followed by liver digestion medium (Thermo Fisher
Scientific, #17703034) for 15min. The liver was removed and dis-
sociated in liver perfusion buffer before filtering through a 100 μm
strainer (Thermo Fisher Scientific).
Hepatocytes were washed 3 times with low glucose DMEM (D6046;
Sigma-Aldrich, St. Louis, MO) supplemented with 10mM Hepes
(Thermo Fisher Scientific, #15630080), 5% charcoal stripped fetal
bovine serum (FBS) (Thermo Fisher Scientific, #12329782) and peni-
cillin/streptomycin (50 U/mL; 50 μg/mL).
Hepatocytes viability was determined by the trypan blue exclusion
assay and a viability of> 90% was routinely observed. Hepatocytes
were seeded at a final density of 2.5× 105 cells/well onto type I col-
lagen coated 12-well plates in attachment medium (William’s E media,
#12551032, Thermo Fisher Scientific, 10% FBS, penicillin/strepto-
mycin (50 U/mL; 50 μg/mL), and 10 nM insulin (Sigma-Aldrich, #
I9278). The medium was changed 2 h after plating to O/N media
consisting of Medium 199 (Thermo Fisher Scientific, #31150022), 5%
FBS, penicillin/streptomycin (50 U/mL; 50 μg/mL) and 1 nM insulin.
All experiments were performed on the second day.
4.3.4. Transfection and Luciferase assays
For dose-response and specificity assays, COS-1 cells were seeded at
density 7×104 cells/well in 24-well plates. After 18–24 h, cells were
transfected with 0.1 µg GAL4-DBD-NR-LBD expression plasmids, 0.2 µg
5×UAS-SV40 Firefly Luciferase reporter plasmid, and 0.05 µg Renilla
Luciferase-coding internal control (pRL-CMV) plasmid, or 0.2 µg full-
length PPAR and RXR-expressing plasmids, with 0.2 µg of any of the
CPT1A- or PLIN1-driven reporters, and 0.05 µg pRL-CMV. Transfections
were carried out using Lipofectamine® 2000 reagent (Invitrogen,
#11668). After 6 hours, the cells were treated with either ADAM, PIRI,
or ROSI in DMSO (final concentration of 0.1 %).
After 18 hours of incubation, cells were washed with PBS and lysed
in Passive Lysis Buffer (Promega, Madison, WI). Dual-Luciferase®
Reporter Assays (Promega, #E1960) were run on a Synergy 2 plate
reader (BioTek® Instruments, Winooski, VT) according to manu-
facturer’s manual. Readings of Firefly Luciferase were normalized to the
Renilla Luciferase readings, and data from at least three independent
transfections experiments run in quadruplicates are presented.
4.3.5. Cytotoxicity assays
Two assays were performed to evaluate the compounds cytotoxic
effects. The LDH Cytotoxicity assay measure Lactate dehydrogenase
(LDH) leaking from damaged or lysed cells into cell media, while the
XTT-based Cell Viability assay is based on measurement of ubiquinone
cycle activity as part of the electron transport chain of viable cells. The
assays were performed with COS1 cells using the Cytotoxicity Detection
Kit (LDH) (Roche, #11644793001) and the In Vitro Toxicology Assay
Kid (XTT based) (Sigma-Aldrich, #TOX2-1KT) according to manu-
facturer’s manuals. Absorbance were read using Synergy H1 Hybrid
Multi-Mode Microplate Reader (Biotek® Instruments) at 492/750 and
450/690 nm for the LDH and XTT assay, respectively.
4.3.6. Real-time quantitative PCR
RNA was isolated using the RNeasy® Mini kit (Qiagen, #74104)
according to the manufacturers manual with following modifications:
Lysates from cells with high fat content, e.g. SGBS cells after differ-
entiation, were mixed 1:1 with 70 % ethanol in high salt solution
(0.45M NaCl/0.24M Na-acetate), before applied to the columns. DNase
digestion was performed on-column before washing and eluting of
RNA. Isolated RNA (500 ng) was reverse transcribed into cDNA using
the High Capacity cDNA Reverse Transcription kit
(AppliedBiosystems™, #4368814) according to manufacturer’s manual
in a total volume of 20 µL per reaction.
Real-time quantitative PCR (qPCR) was performed with 2.5 µL di-
luted cDNA, equivalent to 12.5 ng RNA, in a 10 µL reaction mix using
Kapa SYBR FAST qPCR Master Mix Universal (KapaBiosystems,
#KK4601) on a Bio-Rad CFX96 Touch™ Real-Time PCR Detection
System (Bio-Rad Laboratories). The gene expression was normalized to
TATA-binding protein (TBP), and relative mRNA expression levels were
calculated by the comparative threshold method.
Assay primers were designed with Primer-BLAST software (NCBI,
Bethesda, MD, USA). Primer sequences are listed in Table S1 and S2
(Supporting information).
4.3.7. Staining of neutral lipids
Cells were washed with PBS, fixed in 4 % paraformaldehyde in PBS
for 15 minutes, washed with PBS and dH2O, and stained with Oil Red O
working solution (0.3 % Oil Red O (Sigma-Aldrich, #O0625) in 60 %
isopropanol) for 15 minutes. After staining, cells were washed with
dH2O and PBS. The stained cells were inspected and photographed with
an Olympus® CKX41 inverted microscope (Olympus, Hamburg,
Germany) equipped with a ColorView Illu light microscope CCD camera
(Olympus) and cell* imaging software v.3.4 (Olympus). All images
were processed using Adobe Photoshop CS6 (Adobe Systems Inc, San
Jose California, USA).
4.3.8. Statistical analysis
Statistical analysis were performed using GraphPad Prism 6
(GraphPad Software Inc., San Diego, CA, USA). Statistical differences
between groups were analysed as specified in the Figure legends. Alpha
levels were set to 0.05 for all analyses.
4.4. Docking studies
The Internal Coordinate Mechanics (ICM) program50 was used for
docking of ADAM, OFAI and OFAII into the ligand binding domain
(LBD) of PPARα and PPARγ. The LBDs were kept rigid while the
compounds were free to move during docking. Compounds were
docked into several LBD X-ray structures, to account for conformational
differences of the binding pocket seen with co-crystallization of struc-
turally diverse ligands. For PPARγ docking, the X-ray structures (PDB
entries) 2VSR, 2VST, 2VV0, 2VV1 and 2VV4 were used, while the
PPARα docking were performed with the 2P54 and 3G8I X-ray struc-
tures. Prior to docking, crystallographic water molecules, ions and the
co-crystallized agonist were removed, while hydrogen atoms were
added and optimized using the ECEPP/3 force field. The compounds
were built using ICM and optimized before docking. Grid maps that
included amino acids within 5 Å of the co-crystallized agonists in the
LBD-agonist complexes with a grid spacing of 0.5 Å were calculated
before docking. Ligand conformer sampling in vacuo and Monte Carlo
global energy optimization were used to generate docking poses.51 The
obtained docking poses were scored using the Virtual Ligand Screening
(VLS) module of the ICM program. The VLS scoring function uses steric,
entropic, hydrogen bonding, hydrophobic and electrostatic terms to
calculate the score and also includes a correction term proportional to
the number of atoms in the ligand to avoid bias towards larger li-
gands.52 Each docking was run in three parallels.
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